

**RECEIVED
CENTRAL FAX CENTER****FEB 10 2006****PATENT****IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Application Number: 10/801,085
Applicant: PHILLIPS, E.
Filed: 03/15/2004
TC/A.U.: 1626
Examiner: SAFED, Kamal A.

AstraZeneca Docket No. A1695-5P US
Customer No. 22466

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE

Sir:

This is a response to the Office action dated 01/10/2006.

Response to Election/Restriction Requirement - is on page 2 of this paper.

Amendments to the specification - None.

Amendments to the Claims - None.

Amendments to the Drawings - None.

CERTIFICATE OF FACSIMILE TRANSMISSION (37 C.F.R. § 1.8)

The undersigned hereby certifies that the attached papers and/or fee are being facsimile transmitted to the United States Patent and Trademark Office at the telephone number shown below on the date shown below.


Facsimile number: 1-571-273-8300

Date: February 10, 2006

Kenneth F. Mitchell

Reg. No. 42,007

Signature




Application No. 10/801,085
Response dated February 10, 2006
Reply to Office action dated 01/10/2006

Response to Election/Restriction Requirement:

Applicants elect without traverse the invention of Group I, that is, claims of 1- 8 drawn to a product classified in various subclasses of class 514.

Applicants further elects a single compound, that is, a compound having a structure of Formula 1,



wherein: m is 1; n and p are 0; W is two hydrogens; X is O; Y is N, and D, G and A are CH.

Such a compound is the compound spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine] shown in Example 1, of structure

